Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping point,” says Zhen Su...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news
Can Payers Trust Our Data?
The potential for real-world data to be used on a mass scale to demonstrate the effectiveness and value of medicines is great, promising benefits for all parties including better health outcomes and lower premiums for patients and higher prices for those selling the most effective treatments.Yet, while the use of real-world evidence is growing, a major impediment to its broader and faster adoption is the potential trust gap. After all, how can payers be sure that pharma ’s data tell a true and accurate story about patient outcomes?Payers are increasingly questioning the data they are provided with, says Michelle Hoiseth,...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Can Payers Trust Our Data?
The potential for real-world data to be used on a mass scale to demonstrate the effectiveness and value of medicines is great, promising benefits for all parties including better health outcomes and lower premiums for patients and higher prices for those selling the most effective treatments.Yet, while the use of real-world evidence is growing, a major impediment to its broader and faster adoption is the potential trust gap. After all, how can payers be sure that pharma ’s data tell a true and accurate story about patient outcomes?Payers are increasingly questioning the data they are provided with, says Michelle Hoiseth,...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Diving for Data
Discussion around this is definitely part of the public discourse now but this is going to turn slowly like an ocean liner as incentives become more aligned.“The reimbursement of volume-based agreements is such a complex calculation to unwind, and people acknowledge that it is sensible but a hard thing to do. It takes a lot to move people off tried-and-true, low-risk ways of measuring the performance of a drug.Related Content: Rid Yourself Of Dirty DataTalking The Same LanguageNavigating the ChaosSeeking the Holy Grail of RWEThe Naked Truth About Outcomes-Based PricingPrimary Event: Value Summit USA 2018Pr éci...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
